电子健康档案中价格透明干预对临床医生住院实验室检查开单的影响:PRICE随机临床试验
PRICE试验在费城3家医院开展,比较1年干预期与1年干预期前阶段,将60组住院实验室检查随机分为显示Medicare允许费用组(30组)与不显示组(30组),纳入98 529例患者共142 921次住院。调整时间趋势和患者特征后,干预组与对照组相比,整体检验开单行为无显著变化(每患者日0.05项检查,95%CI -0.002至0.09,P=0.06),相关费用亦无显著变化(每患者日0.24美元,95%CI -0.42至0.91,P=0.47)。探索性亚组分析发现,ICU住院患者每患者日开单减少0.16项(95%CI -0.31至-0.01,P=0.04),无ICU住院患者增加0.13项(95%CI 0.08至0.17,P<0.001)。实际执行的检查在干预组相对对照组小幅显著增加(每患者日0.08项,95%CI 0.03至0.12,P<0.001)。
要点
- 在3家医院142 921次住院中,显示Medicare允许费用未显著改变整体检验开单行为(每患者日0.05项检查,95%CI -0.002至0.09,P=0.06)。
- 整体相关费用亦无显著变化(每患者日0.24美元,95%CI -0.42至0.91,P=0.47)。
- 探索性亚组:ICU住院患者每患者日开单减少0.16项(95%CI -0.31至-0.01,P=0.04),无ICU住院患者增加0.13项(95%CI 0.08至0.17,P<0.001)。
- 实际执行的检查在干预组相对对照组小幅显著增加(每患者日0.08项,95%CI 0.03至0.12,P<0.001)。
- 按费用价值最高四分位组每患者日开单减少0.01项(95%CI -0.02至-0.01,P=0.04),最低四分位组增加0.03项(95%CI 0.002至0.06,P=0.04)。
适用人群与场景
- 费城3家医院住院患者,纳入98 529例患者共142 921次住院,平均(SD)年龄54.7(19.0)岁,56.9%女性(81 291例),51.9%白人(74 165例),38.9%黑人(55 526例)。
- 干预对象为住院实验室检查组(共60组),而非直接针对患者。
研究设计与关键结果
- 研究类型:随机临床试验(PRICE试验),比较1年干预期与1年干预期前阶段,调整时间趋势和患者特征,在3家医院开展,纳入142 921次住院。
- 干预:住院实验室检查组随机分为显示Medicare允许费用组(30组)与不显示组(30组),在电子健康档案中呈现。
- 主要终点:每患者日开单检查数,干预组与对照组相比无显著变化(0.05项,95%CI -0.002至0.09,P=0.06)。
- 次要终点:每患者日相关费用无显著变化(0.24美元,95%CI -0.42至0.91,P=0.47);实际执行检查每患者日小幅显著增加(0.08项,95%CI 0.03至0.12,P<0.001)。
- 探索性亚组:ICU住院患者每患者日开单减少0.16项(95%CI -0.31至-0.01,P=0.04),无ICU住院患者增加0.13项(95%CI 0.08至0.17,P<0.001)。
- 探索性亚组:按费用价值最高四分位组每患者日开单减少0.01项(95%CI -0.02至-0.01,P=0.04),最低四分位组增加0.03项(95%CI 0.002至0.06,P=0.04)。
证据类型、等级与局限
- 证据类型:随机临床试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:显示Medicare允许费用未导致整体临床医生开单行为或相关费用的显著改变。
- 探索性亚组提示ICU住院患者与无ICU住院患者开单变化方向相反,但原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Many health systems are considering increasing price transparency at the time of order entry. However, evidence of its impact on clinician ordering behavior is inconsistent and limited to single-site evaluations of shorter duration.
OBJECTIVE: To test the effect of displaying Medicare allowable fees for inpatient laboratory tests on clinician ordering behavior over 1 year.
DESIGN, SETTING, AND PARTICIPANTS: The Pragmatic Randomized Introduction of Cost data through the electronic health record (PRICE) trial was a randomized clinical trial comparing a 1-year intervention to a 1-year preintervention period, and adjusting for time trends and patient characteristics. The trial took place at 3 hospitals in Philadelphia between April 2014 and April 2016 and included 98 529 patients comprising 142 921 hospital admissions.
INTERVENTIONS: Inpatient laboratory test groups were randomly assigned to display Medicare allowable fees (30 in intervention) or not (30 in control) in the electronic health record.
MAIN OUTCOMES AND MEASURES: Primary outcome was the number of tests ordered per patient-day. Secondary outcomes were tests performed per patient-day and Medicare associated fees.
RESULTS: The sample included 142 921 hospital admissions representing patients who were 51.9% white (74 165), 38.9% black (55 526), and 56.9% female (81 291) with a mean (SD) age of 54.7 (19.0) years. Preintervention trends of order rates among the intervention and control groups were similar. In adjusted analyses of the intervention group compared with the control group over time, there were no significant changes in overall test ordering behavior (0.05 tests ordered per patient-day; 95% CI, -0.002 to 0.09; P = .06) or associated fees ($0.24 per patient-day; 95% CI, -$0.42 to $0.91; P = .47). Exploratory subset analyses found small but significant differences in tests ordered per patient-day based on patient intensive care unit (ICU) stay (patients with ICU stay: -0.16; 95% CI, -0.31 to -0.01; P = .04; patients without ICU stay: 0.13; 95% CI, 0.08-0.17; P < .001) and the magnitude of associated fees (top quartile of tests based on fee value: -0.01; 95% CI, -0.02 to -0.01; P = .04; bottom quartile: 0.03; 95% CI, 0.002-0.06; P = .04). Adjusted analyses of tests that were performed found a small but significant overall increase in the intervention group relative to the control group over time (0.08 tests performed per patient day, 95% CI, 0.03-0.12; P < .001).
CONCLUSIONS AND RELEVANCE: Displaying Medicare allowable fees for inpatient laboratory tests did not lead to a significant change in overall clinician ordering behavior or associated fees.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02355496.
参考来源
- Sedrak MS, Myers JS, Small DS, et al. Effect of a Price Transparency Intervention in the Electronic Health Record on Clinician Ordering of Inpatient Laboratory Tests: The PRICE Randomized Clinical Trial. JAMA Intern Med. 2017. PMID: 28430829. doi:10.1001/jamainternmed.2017.1144
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。